Particle.news
Download on the App Store
6 ARTICLES
·
5h ago

Wegovy Goes on Sale in Argentina Pharmacies After ANMAT Clearance for Obesity Treatment

Novo Nordisk says it is negotiating insurance coverage, offering a patient‑assistance program.

ARCHIVO – Una mujer sostiene una dosis de Wegovy, un fármaco usado para la pérdida de peso, en su vivienda de Front Royal, Virginia, el 1 de marzo de 2024. (AP Foto/Amanda Andrade-Rhoades, Archivo)
ESPECIAL 80 AÑOS OBESIDAD ID:10326654 Una pluma inyectora de semaglutida vendida por Novo Nordisk como Wegovy para el tratamiento la obesidad en casa un paciente Wenatchee Washington 3 junio 2024. Mientras los pacientes se plantean fármacos Ozempic Zepbound y Mounjaro tratar expertos afirman que elegir mejor cada persona no es sencillo. (M. Scott Brauer/The New York Times) - FTP CLARIN cprofetico_Semaglutida.jpg Z Invitado
Image

Overview

  • The high‑dose semaglutide injection is authorized for adults with obesity or overweight plus a related condition, and for adolescents from age 12 weighing over 60 kg.
  • Weekly pens are available in graduated doses up to 2.4 mg, with the 2.4 mg pack priced around ARS 696,919 and the 1 mg option roughly matching Ozempic at about ARS 355,000.
  • Clinical studies cited by specialists report average weight loss near 17% with about one‑third of patients losing around 20%, alongside reported cardiovascular and renal benefits from SELECT.
  • Doctors and the Health Ministry warn against aesthetic or unsupervised use, noting gastrointestinal side effects such as nausea, diarrhea, changes in bowel habits, headache, and vomiting.
  • Local competition is building, with sources telling La Nacion that Elea plans a similar semaglutide launch in mid‑November priced near ARS 250,000 for a month at 2.4 mg.